基本情况
马超，医学博士，上海交通大学医学院附属新华医院副主任医师、硕士生导师。

研究领域
甲状腺癌和肿瘤分子靶向治疗

主持项目

  1. 131I-WBS阴性/Tg阳性分化型甲状腺癌复发或转移灶NIS与GLUT表达的相关性研究（2013.1-2016.12），国家自然科学基金面上项目资助 (项目批准号：81271612)，在研
  2. 碘-131联合99Tc-MDP治疗分化型甲状腺癌骨转移双效的分子机制研究（2013.9.1-2015.8.31），上海市浦江人才计划项目（项目编号：13PJD022），在研
  3. 188Re-NT6-11VIP7-28介导IL12和紫杉醇长循环脂质体综合治疗乳腺癌的机理研究（2007.1-2010.12），国家自然科学基金青年项目资助（30700185），已结题

荣誉奖励
  1. 2011年碘-131与分化型甲状腺癌相关研究获得青岛市自然科学三等奖
  2. 2011年青岛市第十届优秀论文三等奖（题目Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer）
  3. 2009年6月荣获青岛市卫生系统十大杰出青年奖

学术兼职
  1. 中华医学会核医学专科分会第九届全国委员
  2. 中国医师协会核医学分会第一届委员

论文代表
  1. 唐立岷，马超*，18F-FDG PET在诊断浸润性乳腺癌和淋巴结转移中的价值，上海交通大学学报（医学版），2012；32（6）：761-765
  2. 马超，谢加伟，匡安仁等，bcl-2/bcl-xl和bcl-2反义寡核苷酸对乳腺癌细胞增殖和凋亡的影响，四川大学学报（医学版），2009；40（5）：780-784 
  3. 马超，匡安仁，不同类型长循环脂质体在动物体内的分布和药代动力学研究，四川大学学报（医学版），2011；（2）：249-251
  4. 马超，匡安仁，黄蕤，唐恭顺，阴离子长循环脂质体在瘤鼠体内分布和反义显像，生物医学工程学杂志，2011：28（2）：233-237（EI收录）
  5. Chao Ma, Jiawei Xie, An-ren Kuang. The Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-body Scan. J Nucl Med. 2005; 46(9): 1473-1480
  6. Chao Ma, An-ren Kuang, Jiawei Xie, et al. Is Blind 131I Therapy Justified for Patients with Negative Tg and Positive 131I WBS J Nucl Med. 2005; 46(7): 1164-1170 
  7. Ma Chao, Kuang AR. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev. 2009; (1): CD006988
  8. Chao M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. Clin Oncol (R Coll Radiol). 2010; 22(6): 438-447
  9. Ma C, Xie J, Lou Y, Gao Y, Zuo S, Wang X. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur J Endocrinol. 2010; 163(2): 177-183
  10. Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.Cochrane Database Syst Rev. 2010; 11: CD008302
  11. Chao Ma, Jiawei Xie, Qingfeng Chen, Guoming Wang, Shuyao Zuo. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. Cochrane Database Syst Rev. 2009, (4): CD007956
  12. Ma Chao, Xie Jiawei, Jiang Zhongxin, Anren Kuang. Anionic long-circulating liposomes for delivery of radioiodinated antisense oligonucleotides. EJLST (European Journal of Lipid Science and Technology). 2010; 112: 545-551
  13. Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010; 37(9): 1778-1785
  14. Ma Chao, Kuang AR. Radioiodine treatment for pediactric Graves' disease. Cochrane Database Syst Rev. 2008, 16 (3): CD006294
  15. Chao M, Jiawei X, Guoming W, Jianbin L, Wanxia L, Driedger A, Shuyao Z, Qin Z. Radioiodine treatment for pediatric hyperthyroid Grave's disease. Eur J Pediatr. 2009; 168(10): 1165-1169
  16. Ma C, Xie J, Huang X, Wang G, Wang Y, Wang X, Zuo S. Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl Med Commun. 2009; 30(8): 586-593
  17. Chao Ma, Jizheng Lin, Jiawei Xie, Guoming Wang, Zuo Shuyao. Delivery of radioiodinated antisense oligonucleotides in long circulating liposomes in vivor. EJLST.2011, 113(9): 1106-1112
  18. Jiawei Xie, Chao Ma, Jizheng Lin, et al. An anionic long-circulating liposome that improves radioiodinated antisense oligonucleotide delivery in vitro and in vivo. Advances in Polymer Technology. 2012; 31(1): 20-28
  19. Cheng W, Ma C, Fu H, et al. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2013; 98(4): 1353-1360 (IF=6.43)